112 related articles for article (PubMed ID: 7581527)
1. [BCG vs. BCG plus recombinant alpha-interferon 2b in superficial tumors of the bladder].
Bercovich E; Deriu M; Manferrari F; Irianni G
Arch Ital Urol Androl; 1995 Sep; 67(4):257-60. PubMed ID: 7581527
[TBL] [Abstract][Full Text] [Related]
2. [BCG vs interferon A for prevention of recurrence of superficial bladder cancer. A prospective randomized study].
Kälble T; Beer M; Mendoza E; Ikinger U; Link M; Reichert HE; Frangenheim T; Klein E; Fabricius PG
Urologe A; 1994 Mar; 33(2):133-7. PubMed ID: 8178407
[TBL] [Abstract][Full Text] [Related]
3. Intravesical immunoprophylaxis in recurrent superficial bladder cancer (Stage T1): multicenter trial comparing bacille Calmette-Guérin and interferon-alpha.
Jimenez-Cruz JF; Vera-Donoso CD; Leiva O; Pamplona M; Rioja-Sanz LA; Martinez-Lasierra M; Flores N; Unda M
Urology; 1997 Oct; 50(4):529-35. PubMed ID: 9338727
[TBL] [Abstract][Full Text] [Related]
4. Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer.
Joudi FN; Smith BJ; O'Donnell MA;
Urol Oncol; 2006; 24(4):344-8. PubMed ID: 16818189
[TBL] [Abstract][Full Text] [Related]
5. [Prophylactic effect of inductive intravesical instillation of Bacillus Calmette-Guerin on postoperative recurrence of bladder cancer].
Yi SH; Ye G; Wang XW; Jin HS; Zhang YN; Yan ZL
Ai Zheng; 2008 Nov; 27(11):1208-11. PubMed ID: 19000455
[TBL] [Abstract][Full Text] [Related]
6. [Results of adjuvant intravesical Bacillus Calmette-Guérin therapy for grade 3 superficial bladder cancer].
Yumura Y; Oogo Y; Takase K; Hamano A; Yamashita Y; Noguchi S; Satomi Y
Hinyokika Kiyo; 2004 Nov; 50(11):767-71. PubMed ID: 15628536
[TBL] [Abstract][Full Text] [Related]
7. [Intravesical BCG vaccine in bladder cancer].
Beisland HO; Sander S
Tidsskr Nor Laegeforen; 1989 Jun; 109(17-18):1891-2. PubMed ID: 2749672
[TBL] [Abstract][Full Text] [Related]
8. [Treatment of superficial bladder tumors with intravesical BCG].
Miskowiak J; Jensen JS
Ugeskr Laeger; 1992 Mar; 154(10):640-3. PubMed ID: 1542971
[TBL] [Abstract][Full Text] [Related]
9. [Intravesical immunotherapy with BCG vaccine in superficial carcinoma of the urinary bladder].
Pacík D; Vít V; Turjanica M
Rozhl Chir; 1997 Oct; 76(10):482-5. PubMed ID: 9471737
[TBL] [Abstract][Full Text] [Related]
10. [Mechanism of preventing the recurrence of bladder carcinoma by intravesical instillation of BCG plus IL-2].
Wen R; Zhou G; Xie S; Lian B; Sun X; Chen J
Zhonghua Wai Ke Za Zhi; 1998 Apr; 36(4):247-8. PubMed ID: 11825381
[TBL] [Abstract][Full Text] [Related]
11. [Intravesical instillation in the treatment of superficial tumors of the bladder].
Chopin DK
Prog Urol; 1998 Apr; 8(2):268-73. PubMed ID: 9615941
[TBL] [Abstract][Full Text] [Related]
12. Intravesical therapy comparing BCG, adriamycin, and thiotepa in 200 patients with superficial bladder cancer: a randomized prospective study.
Martinez-Pineiro JA; Jimenez León J; Martinez-Pineiro L; Fiter L; Mosteiro JA; Navarro J; García Matres MJ; Cárcamo P
Prog Clin Biol Res; 1989; 310():237-52. PubMed ID: 2505269
[TBL] [Abstract][Full Text] [Related]
13. What is the optimal treatment strategy for T1 bladder tumors?
Babjuk M
Eur Urol; 2010 Jan; 57(1):32-4. PubMed ID: 19846251
[No Abstract] [Full Text] [Related]
14. Bacillus Calmette-Guérin plus intravesical interferon alpha-2b in patients with superficial bladder cancer.
Stricker P; Pryor K; Nicholson T; Goldstein D; Golovsky D; Ferguson R; Nash P; Ehsman S; Rumma J; Mammen G; Penny R
Urology; 1996 Dec; 48(6):957-61; discussion 961-2. PubMed ID: 8973689
[TBL] [Abstract][Full Text] [Related]
15. Combined low-dose intravesical immunotherapy (BCG + interferon alpha-2b) in the management of superficial transitional cell carcinoma of the urinary bladder: a five-year follow-up.
Mohanty NK; Malhotra V; Nayak RL; Arora RP
J Chemother; 2002 Apr; 14(2):194-7. PubMed ID: 12017377
[TBL] [Abstract][Full Text] [Related]
16. [Lower toxicity with the topical low-dose BCG therapy of superficial bladder carcinoma?].
Mack D; Frick J
Urologe A; 1992 Mar; 31(2):88-90. PubMed ID: 1561732
[TBL] [Abstract][Full Text] [Related]
17. Immunoprophylactic intravesical application of bacillus Calmette-Guerin after transurethral resection of superficial bladder cancer.
Librenjak D; Situm M; Eterovic D; Dogas Z; Gotovac J
Croat Med J; 2003 Apr; 44(2):187-92. PubMed ID: 12698510
[TBL] [Abstract][Full Text] [Related]
18. [Intravesical BCG therapy for superficial bladder cancer].
Segawa N; Iwamoto Y; Azuma H; Yamamoto K; Ueda H; Katsuoka Y
Hinyokika Kiyo; 1998 Sep; 44(9):627-31. PubMed ID: 9805666
[TBL] [Abstract][Full Text] [Related]
19. BCG in the management of superficial bladder cancer.
Guinan P; Richardson C; Hanna M; Rubenstein M
Prog Clin Biol Res; 1989; 303():447-53. PubMed ID: 2675002
[TBL] [Abstract][Full Text] [Related]
20. Intravesical instillation of bacille Calmette-Guérin for superficial bladder cancer: cost-effectiveness analysis.
Uchida A; Yonou H; Hayashi E; Iha K; Oda M; Miyazato M; Oshiro Y; Hokama S; Sugaya K; Ogawa Y
Urology; 2007 Feb; 69(2):275-9. PubMed ID: 17320663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
